A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Conditions
- Geographic Atrophy of the Macula
Interventions
- DRUG: GAL-101
- DRUG: Placebo
Sponsor
Galimedix Therapeutics Inc
Collaborators